A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization

Key facts

Study ID

NCT06685068

Run by

Genmab

People needed

23

Starts

2024-11-13

Expected to finish

2026-03-30

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• START Midwest — Grand Rapids, Michigan, United States
• START San Antonio — San Antonio, Texas, United States
• START Mountain Region — West Valley City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.